NCT04732260View on ClinicalTrials.gov

Prenatal Treatment of Congenital Cytomegalovirus Infection With Letermovir Randomized Against Valaciclovir - CYMEVALIII STEP1

NACompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

June 11, 2021

Primary Completion Date

November 5, 2021

Study Completion Date

November 12, 2021

Conditions
Pregnant Women Undergoing TOPTOP - Failed Attempted Termination of Pregnancy
Interventions
DRUG

Letermovir

"Each patient will receive 1 tablet of Letermovir (240 mg or 480 mg /day) during 3 days before TOP.~5 women will receive 240 mg. 5 women will receive 480 mg."

Trial Locations (1)

75015

Hôpital Necker - Enfants malades, Paris

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER